METADATA
last updated: 2026-02-23 RT
file_name: _context-commentary_various-papers.md
category: various
subcategory: papers
words: 799
tokens: 1112


CONTENT

## Context
This subcategory contains a subset of scientific papers on pandemic testing and screening that FloodLAMP collected during its period of operation (2020–2023). These are papers that do not fit into more specific subcategories — papers-lamp covers LAMP-specific literature.

The collection spans several themes. Foundational testing methodology is represented by a primer on RT-qPCR testing (Bustin & Nolan, 2020) and a review of nucleic acid testing approaches for COVID-19 detection (Esbin et al., 2020, from the Tjian lab). Sample collection and alternative specimen types appear in work on saliva-based testing evaluated across multiple methods (Nagura-Ikeda et al., 2020) and a preprint on post-disease divergence in detection between nasopharyngeal swabs and saliva (Turner et al., 2021, from Curative).

Scaling capacity through laboratory design and pooling is the topic of The Innovative Genomics Institute's blueprint for a "pop-up" SARS-CoV-2 testing lab (IGI Testing Consortium, 2020, included as both preprint and published Nature Biotechnology versions) and the CLIAHUB rapid-deployment paper and companion how-to guide (Crawford et al., 2020) document efforts to stand up high-throughput testing infrastructure quickly. The Technion preprint on multi-sample pooling (Yelin et al., 2020) addresses efficiency gains under resource constraints.

Population-level screening strategy appears in the Romer/Taipale/Linnarsson preprint arguing that population-scale testing can suppress spread (2020), the UIUC SHIELD work on surveillance testing frequency (Elbanna & Goldenfeld, 2021) and on saliva-based molecular testing that bypasses RNA extraction (Ranoa et al., 2020), and viral shedding modeling from the Fred Hutch group (Goyal et al., 2020). Rapid antigen test performance is covered by the Cochrane review (Dinnes et al., 2021) — included here via a Guardian article summarizing its key finding that rapid antigen tests correctly identify only about 58% of asymptomatic infections — and a community evaluation of the Abbott BinaxNOW test (Pollock et al., 2021).

An AI literature review was created with ChatGPT 5.2 Pro Extended and is contained in the following archive file. It has a several AI responses that relate to pandemic preparedness and response.
_AI_Literature Review - Pandemic Testing and Screening Strategy.md


## Commentary
Several papers in this collection have particular significance beyond their scientific content, either because they directly influenced FloodLAMP's founding or because they represent important and sometimes cautionary episodes in the COVID testing story.

The Doudna Lab's blueprint for a pop-up SARS-CoV-2 testing lab was the paper that inspired the founding of FloodLAMP in the spring of 2020. The supplement was especially valuable — it provided extensive practical details including regulatory and compliance guidance that was difficult to find elsewhere at the time. It's our understanding that the Doudna Lab's testing operation became the focal point for COVID testing on the UC Berkeley campus.

The CLIA HUB paper, documenting the Chan Zuckerberg Biohub and UCSF effort to rapidly deploy high-throughput SARS-CoV-2 testing, is notable both for the ambition of the project and for how it ended. The mobilization of scientists and researchers to build this infrastructure was impressive and can serve as a model for similar efforts. A companion 10 mintue YouTube video ((https://youtu.be/LgRQge1y0U8?si=an_sDhdm5TDlUQzC)) provides overview. The project operated as a CLIA Hub with ambitions to scale and distribute its model more broadly, but it abruptly ceased operations. According to someone in leadership on the project, the reason was regulatory blowback risk. Why this effort was not scaled — why it did not play a larger role in California's or the nation's testing response — deserves attention. Comparing this effort to other university-based testing initiatives would be informative.

Curative is worth noting as an entity, not just for its paper on post-disease detection divergence between swabs and saliva. Curative was a biotech startup pivoted to COVID testing by entrepreneur Fred Turner. It grew quickly into a significant component of the testing landscape, but encountered regulatory challenges and conflict with the FDA — episodes that are relevant to understanding the broader dynamics of COVID-era diagnostics.

The University of Illinois' SHIELD program was a competitor of sorts to SalivaDirect, with a very similar assay. A comparison of the similarities and differences between the two programs — their approaches, their outcomes, and their respective paths through regulatory and operational challenges — may be a useful exercise for anyone studying decentralized molecular testing.

The Tjian paper (Esbin et al., 2020), although published early in the pandemic, was the best comprehensive review of COVID testing we knew of at the time and served as an important reference.

Paul Romer's preprint on population-scale testing to suppress spread was published in April 2020, early in the pandemic, when he was one of the most visible advocates for testing as a primary tool for pandemic control. Following his public advocacy and writing throughout the pandemic trajectory — not just this single paper — would be a useful lens for understanding how the role of testing was debated in real time.